Latest Conference Articles

Teclistamab Demonstrates Encouraging Efficacy, Safety at the RP2D in Relapsed/Refractory Multiple Myeloma

Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.

C-CAR066 Achieves High Marks in Relapsed/Refractory B-NHL

C-CAR066 exhibited a favorable safety profile and promising efficacy in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.

Men With African Ancestry Less Likely to Receive Early Genomic Profiling in Prostate Cancer

Findings of a study examining comprehensive genomic profiling shed more light on disparities in prostate cancer care.

Alrizomadlin/Pembrolizumab Induces Early Efficacy in Unresectable Melanoma or Advanced Solid Tumors

The addition of alrizomadlin to pembrolizumab yielded promising preliminary efficacy and was tolerable in patients with unresectable or metastatic melanoma or advanced solid tumors that have been resistant to immunotherapy agents.

TURBT Plus Nivolumab/Chemo Shows Promise in Muscle-Invasive Bladder Cancer

Combining transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise as a bladder-sparing treatment strategy in patients with muscle-invasive bladder cancer.

KCd Consolidation Does Not Show Noninferiority to ASCT in Transplant-Eligible, Newly Diagnosed Myeloma

The 2-year progression free survival achieved with carfilzomib, cyclophosphamide, and dexamethasone consolidation did not prove to be noninferior to up-front autologous stem cell transplantation in newly diagnosed, transplant-eligible patients with multiple myeloma, although the margin is small.

Fracture Risk Reduced With BPAs During Radium-223/Enzalutamide Treatment in mCRPC

Bone-protecting agents utilized during treatment with radium-223 plus enzalutamide reduced the risk for fractures in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.

Regorafenib/Avelumab Combo Elicits Modest Activity in Heavily Pretreated Biliary Tract Cancer

The addition of regorafenib to avelumab demonstrated modest anti-tumor responses and survival benefit in patients with heavily pretreated biliary tract cancer.

C-CAR039 Demonstrates Promising Efficacy, Safety in Relapsed/Refractory B-NHL

The second-generation 4-1BB bi-specific CAR T-cell therapy C-CAR039 improved response rates and showed favorable safety in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Panitumumab Plus 5-FU/Leucovorin Maintenance Improves PFS in RAS Wild-Type Metastatic CRC

The addition of panitumumab to 5-fluorouracil and leucovorin significantly improved progression-free survival as a maintenance treatment over 5-FU/leucovorin alone in patients with RAS wild-type metastatic colorectal cancer.

Trastuzumab Deruxtecan Maintains Antitumor Activity in HER2+ mCRC

Final results of the DESTINY-CRC01 trial were consistent with primary analysis, establishing the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-overexpressing metastatic colorectal cancer.

Dr. Zalcberg on the Efficacy of Intra-Patient Dose Escalation With Ripretinib in Advanced GIST

John Raymond Zalcberg, discusses the efficacy of intra-patient dose escalation with ripretinib in patients with advanced gastrointestinal stromal tumors, as demonstrated in an analysis of the phase 3 INVICTUS trial.

Dr. Tannir on Results With Telaglenastat/Cabozantinib in mRCC

Nazir Tannir, MD, FACP, discusses the efficacy of the combination of telaglenastat and cabozantinib in patients with metastatic renal cell carcinoma, as demonstrated in the phase 2 CANTATA trial.

Tisagenlecleucel Induces High Rates of Durable Response in Relapsed/Refractory Follicular Lymphoma

Tisagenlecleucel led to a high response rate that proved durable, along with a favorable safety profile, in patients with relapsed/refractory follicular lymphoma following treatment with at least 2 prior regimens, according to interim findings from the phase 2 ELARA trial.

Dr. Ailawadhi on the Efficacy of Lisaftoclax in Hematologic Malignancies

Sikander Ailawadhi, MD, discusses the activity of lisaftoclax in patients with hematologic malignancies.

Dr. Short on the Activity of Ponatinib/Blinatumomab in Ph+ ALL

Nicholas J. Short, MD, discusses the efficacy of the combination of ponatinib and blinatumomab in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Pembrolizumab Plus Gemcitabine/Hypofractionated Radiotherapy Demonstrates Promising Efficacy in Muscle-Invasive Bladder Cancer

Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiotherapy appears to be a promising and efficacious, bladder-sparing regimen for patients with muscle-invasive bladder cancer.

Dr. Abou-Alfa on Efficacy With Ivosidenib in IDH1+ Cholangiocarcinoma

Ghassan K. Abou-Alfa, MD, discusses the efficacy of ivosidenib in IDH1-mutant cholangiocarcinoma based on the results of the phase 3 ClarIDHy study.

Dr. Litton on Responses to Talazoparib in BRCA1/2+ Early TNBC

Jennifer Litton, MD, highlights responses to talazoparib seen in patients with BRCA1/2-positive, early triple-negative breast cancer.

First-Line Ibrutinib/Venetoclax Inhibits Response in CLL/SLL

Ibrutinib plus venetoclax produced a complete response and complete response with incomplete bone marrow recovery rate of 56% in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

mFOLFOXIRI/Cetuximab Combo Improves Depth of Response in RAS Wild-Type mCRC

Cetuximab added to mFOLFOXIRI induced superior depth of response than mFOLFOXIRI plus bevacizumab in treatment-naïve patients with RAS wild-type metastatic colorectal cancer.

Lisaftoclax Shows Early Safety, Efficacy in Relapsed/Refractory CLL/SLL and Other Hematologic Cancers

The novel BCL-2 inhibitor lisaftoclax elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and other hematologic cancers.

Cetuximab Misses ORR End Point in RAS Wild-Type, BRAF V600E+ mCRC

The chemotherapy regimen of FOLFOXIRI plus bevacizumab was found to be preferred in terms of antitumor activity compared with FOLFOXIRI plus cetuximab in patients with RAS wild-type, BRAF V600E–mutant metastatic colorectal cancer.

Pertuzumab/Trastuzumab Combo Elicits Clinical Activity in ERBB2/ERBB3+ Uterine Cancer

The combination of pertuzumab and trastuzumab elicited a 37% disease control in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer.

Updates in Genitourinary, Gynecologic Cancers From ASCO 2021: Drs Nick Vogelzang and Erin Crane

Sacituzumab Govitecan Maintains Efficacy Benefit Over Chemo in Metastatic TNBC, Irrespective of Agent

The antibody-drug conjugate sacituzumab govitecan retained benefit in progression-free survival, overall survival, and objective response rate over physician’s choice of therapy, regardless of the chemotherapy agent used.

Pembrolizumab/Axitinib Survival Benefit Sustained in Long-Term Results in RCC

The frontline combination of pembrolizumab plus axitinib continued to show a survival benefit over single-agent sunitinib in patients with renal cell carcinoma.

HRQOL Analysis Further Supports Pembrolizumab/Lenvatinib for Frontline RCC

Frontline treatment with the combination of lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma led to similar health-related quality of life outcomes and disease-related symptom scores vs sunitinib.

SD-101 Plus Pembrolizumab and Paclitaxel Yields Moderate Response Boost in High-Risk, HER2-Negative Breast Cancer

Treatment with intra-tumoral SD-101 in combination with pembrolizumab and paclitaxel resulted in a non-statistically significant increase in estimated pathological complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer across 3 HER2-negative biomarker signature groups.

Prolonged Treatment With Bevacizumab Does Not Yield Further Survival Benefit in Ovarian Cancer

Although prolonged treatment with bevacizumab for up to 30 months is feasible with consistent safety data for patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, the regimen did not improve survival over the standard 15 month treatment regimen.